Brief: Chinese Patent Granted For CytoMed Therapeutics' Licensed iPSC-Based Technology
25/09/2023 12:04
Sept 25 (Reuters) - CytoMed Therapeutics Ltd F98.F :
* CHINESE PATENT GRANTED FOR CYTOMED THERAPEUTICS' LICENSED
IPSC-BASED TECHNOLOGY
Source text for Eikon: ID:nPn9LHVHMa
Further company coverage: F98.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CytoMed Therapeutics
See all newsBrief: Cytomed Therapeutics Limited Announces Receipt Of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Brief: Cytomed Therapeutics Refutes "Misleading" Claims & Reaffirms Clinical Progress
Brief: Cytomed Therapeutics Completes Acquisition Of T Cell Technology From Uk To Treat Cancers In China And India
Brief: CytoMed Therapeutics To Start Dose Level 2 In Angelica Trial Q3 2025
Brief: Cytomed Therapeutics Ltd Files For Mixed Shelf Of Up To $50 Million